Cancer Prevention Pharmaceuticals (Cancer Prevention Pharmaceuticals) Pre-Tax Income : $-5.72 Mil (TTM As of Mar. 2016)

View and export this data going back to 2016. Start your Free Trial

What is Cancer Prevention Pharmaceuticals Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Cancer Prevention Pharmaceuticals's pretax income for the three months ended in Mar. 2016 was $-3.33 Mil. Its pretax income for the trailing twelve months (TTM) ended in Mar. 2016 was $-5.72 Mil. Cancer Prevention Pharmaceuticals's pretax margin was -320.33%.

Cancer Prevention Pharmaceuticals Pre-Tax Income Historical Data

The historical data trend for Cancer Prevention Pharmaceuticals's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cancer Prevention Pharmaceuticals Pre-Tax Income Chart

Cancer Prevention Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Pre-Tax Income

-2.98

-6.01

-5.68

Cancer Prevention Pharmaceuticals Quarterly Data
	Dec13	Dec14	Mar15	Sep15	Dec15	Mar16
Pre-Tax Income	Get a 7-Day Free Trial			-1.61	-2.01	-	-2.40	-3.33

Competitive Comparison of Cancer Prevention Pharmaceuticals's Pre-Tax Income

For the Drug Manufacturers - Specialty & Generic subindustry, Cancer Prevention Pharmaceuticals's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cancer Prevention Pharmaceuticals's Pre-Tax Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cancer Prevention Pharmaceuticals's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Cancer Prevention Pharmaceuticals's Pre-Tax Income falls into.

Cancer Prevention Pharmaceuticals Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Cancer Prevention Pharmaceuticals's Pretax Income for the fiscal year that ended in Dec. 2015 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-3.923	+	-1.761	+	0	+	0.003	+	0
	=	-5.68

Cancer Prevention Pharmaceuticals's Pretax Income for the quarter that ended in Mar. 2016 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-2.128	+	-1.025	+	-0.172	+	0	+	0
	=	-3.33

Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.72 Mil.

Cancer Prevention Pharmaceuticals (AMEX:CPP) Pre-Tax Income Explanation

Cancer Prevention Pharmaceuticals's Pretax Margin for the quarter that ended in Mar. 2016 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-3.325	/	1.038
	=	-320.33%

Cancer Prevention Pharmaceuticals Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Cancer Prevention Pharmaceuticals's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Cancer Prevention Pharmaceuticals (Cancer Prevention Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cancer Prevention Pharmaceuticals Inc (AMEX:CPP) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.canprevent.com

Cancer Prevention Pharmaceuticals Inc is a pharmaceutical company. It was originally incorporated under the laws of the state of Arizona on June 9, 2008, as Cancer Prevention Pharmaceuticals, LLC and on December 22, 2009, Cancer Prevention Pharmaceuticals, Inc. was incorporated in the state of Delaware. The Company currently operates mainly in the development and commercialization of compound CPP-1X, otherwise known as DFMO or eflornithine. It is involved in familial adenomatous polyposis, neuroblastoma and the prevention of recurrence in colon cancer survivors. However, CPP also has therapeutic prevention approaches for prostate cancer, breast cancer, and skin cancers which will be developed together with the National Cancer Institute (as resources become available in the future) and multiple academic partners. Its competitors are Marina Biotech, Inc., SLA Pharma AG, StemSynergy Therapeutics, Inc. and Thetis Pharmaceuticals LLC. The Company holds license to approximately six issued patents in the United States. The Company's activities are subject to risks and uncertainties including failure to obtain required regulatory approvals to market the products, once developed, in the USA or foreign markets.